Virtual Invest Meetup,
May 20th, 2021.

Ticket Information

One of the purposes of Unicorn Lab is promoting beneficial cooperation and partnership between entrepreneurs and investors from the HealthTech, BioTech Industry.

We invite you to join our Virtual Invest Meetup. It is the networking event where top tear Investors meet innovation Startups working to promote Longevity and Health spans.

Date and Time: May 20th, 10 am - 1 pm PT | 1 pm - 4 pm ET | 12 pm - 3 pm CT

It is a great opportunity to learn from Industry Experts and gain life-changing knowledge and insight as well as to find Innovative Solutions and Technologies for your investment portfolio.

The Meetup will start with the Panel Discussion "The Hottest Trends in HealthTech Investment". Experienced and renowned Venture Capital Investors will describe the topic from their perspectives.

The second part will be dedicated to the Presentations of selected HealthTech, LongevityTech, and BioTech Startups. Each entrepreneur will have 10 minutes for their Pitch which will be followed by a Q&A session with invited VCs.

If you are interested in presenting your Startup at the Meetup, please Apply and we will get back to you with feedback 

We are looking forward to meeting you!

 

Speakers
x
Julianne Roseman
Senior Associate, Ventures, Plug and Play Tech Center

Julianne currently leads healthcare investing at Plug and Play where she focuses on digital solutions for patients, provides, and pharma. Plug and Play is a global innovation platform that includes venture capital, business development programs, and corporate innovation. In 2019, Pitchbook named Plug and Play the 2nd most active investor in the US and the 5th most active investor in healthcare services and systems. Julianne is particularly interested in preventive medicine, femtech, and digital therapeutics as well as impact investing. Her recent investments include Helium Health (healthcare software solutions for emerging markets), Rapicare (healthcare supply chain solution in Brazil), and Hyfe (AI for cough detection and analysis). Earlier in her career, Julianne worked on therapeutics investing.

Allan W. May
Venture Partner, Medtech Convergence Fund and Founder, Life Science Angels

Allan joined the Medtech Convergence Fund as a Venture Partner in 2020. MCF is focused on the shift in therapy from intervention to prevention, invasive to non-invasive, and hospitals to the home, improving patient access while lowering the costs of managing disease. MCF is within the $3B family of funds managed by SV Health Investors.

Allan is a founder of Life Science Angels (www.lifescienceangels.org), the largest and most well-known early-stage investment group focused solely on emerging biotech, genomic, medical device, diagnostic and mobile health companies (LSA) and comprised entirely of industry veterans. LSA has invested over $75M in 70 portfolio companies and achieved 24 positive exits, and was named the Top Angel Investment Group in the United States by industry analytical source CB Insights (https://www.cbinsights.com/blog/top-angel-groups-mosaic/).

Previously, Allan was co-founder and Managing Partner of Emergent Medical Partners, a $90M venture fund, focused on medical device and diagnostics. Investments included eValve (Abbott); Nanostim (acq St Jude); CyberHeart (acq Varian); Crux (acq Volcano); StimWave and Relievant.

Allan is also Chairman of FundamentalVR, the leader in utilizing kinesthetic haptic feedback and VR to enable the commercial introduction of new medical devices and procedures, essentially replacing wet and cadaver labs.

In 2018, Allan co-founded Woodside Medical, an incubator helping commercialize U.S. medical technologies in China, with partnerships in Shanghai and Suzhou.

Allan has been founder, Chairman, CEO, or investor in over 80 medtech, biotech, and diagnostic startups. He was a co-founder and Chairman of Nanostim, developer of a Leadless Cardiac pacemaker, which was acquired by St. Jude Medical in 2013, and co-founder of Hyalex Surgical, Inc, developer of a novel artificial cartilage for total joint replacements, and is Chairman of Celero Medical, Noctrix Medical, and

Allan speaks frequently at conferences, universities, and government programs on trends and developments affecting early stage biotech and medical device investing. Allan developed medical device curriculum for Steve Blank’s inaugural groundbreaking program at University of California San Francisco to teach the Lean LaunchPad™ startup methodology in the medical device sector (LLP). He worked with Steve to bring LLP to the National Institutes of Health. LLP has also been adopted by the National Science Foundation as a core curriculum (i-Corps) for entrepreneurs. Previously, Allan served on the boards of directors of both the Kauffman Foundation’s Angel Capital Association and Angel Resource Institute, where he also served as Chairman.

Jun Deng
Investment Partner, Joyance Partners

Jun has over a decade of experience in biomedical innovation and venture capital investment. At Joyance Partners, Jun shaped the investment strategy for health-tech and biotech areas, led the “Inception” program to bridge the relationships between academia and venture, and led more than two dozens of investments globally. So far, Jun has led or been involved in over 50 early-stage investments in the field of healthcare, medtech and biotechnologies and served two board roles. Jun is a mentor in multiple innovation ecosystems, including Singularity University and Healthtech Capital. Jun received her PhD degree in molecular physiology from UCLA.

Bill Hyun, PhD
Venture Partner, Genoa Ventures

Bill is a Venture Partner with Genoa Ventures and a faculty member in the Department of Lab Medicine at the University of California, San Francisco (UCSF). Bill is a respected expert in both basic research and clinical lab application development with a strong concentration on cytometry, optical imaging and genomic technologies. Through strategic partnerships with companies like Becton Dickinson, Zeiss, Danaher and Sony, his lab designed, tested and/or validated over 20 different commercial products. Examples include the FACS Aria, FACS Canto, Sony Spectral Flow Cytometer, Meta Spectral Confocal, quantum dots, and Cytobank. His academic career includes a PhD in Biophysics and an MS in Biochemistry, past joint appointments at UC Berkeley and the Lawrence Berkeley National Lab, three honorary doctorates, and authorship of over 100 peer-reviewed publications.

On the venture side, Bill has co-founded ten biotech startups and has led investment in dozens of others, usually in the seed or series A stage. Example companies include Accuri Cytometers, Zephyrus, Mission Bio, Fluent, Slingshot, CellFe, and Akadeum. Bill is a current board member for five companies, has served as Venture Partner with two Bay Area venture groups focused on early-stage investment, and is closely affiliated with four life tech incubators.

Julia Smila
Co-Founder, Unicorn Lab & Biohacking Congress

Julia has been working in the Venture Capital Industry for more than 5 years, she is experienced in investor relationship management with the main focus on the impact investments in companies working to promote longevity and healthspan.

Julia is passionate about Biohacking. She is the Co-Organiser of Biohacking Congress, the international platform dedicated to furthering the advancement of Biohacking, Health Optimization, Longevity, Wellness, BioTech, and HealthTech.

Julianne Roseman
Senior Associate, Ventures, Plug and Play Tech Center
Allan W. May
Venture Partner, Medtech Convergence Fund and Founder, Life Science Angels
Jun Deng
Investment Partner, Joyance Partners
Bill Hyun, PhD
Venture Partner, Genoa Ventures
Julia Smila
Co-Founder, Unicorn Lab & Biohacking Congress
Investors
x
David Fox
Business Angel, Corporate Development, Modality.ai

I made my first early-stage investment in the late '90s before angel investing turned into an industry with incubators, accelerators, and syndicates. Angel investing enables me to time travel. Every day I get to see the future.

As a serial entrepreneur, I know the challenges of building a business, raising money, and if we're fortunate, finding a path to a solid exit.

My primary investing focus is investing in early-stage companies that will make a positive contribution towards healthier people and our planet.  I typically invest as a syndicate member, though I make an occasional direct investment.

Bill Hyun, PhD
Venture Partner, Genoa Ventures

Bill is a Venture Partner with Genoa Ventures and a faculty member in the Department of Lab Medicine at the University of California, San Francisco (UCSF). Bill is a respected expert in both basic research and clinical lab application development with a strong concentration on cytometry, optical imaging and genomic technologies. Through strategic partnerships with companies like Becton Dickinson, Zeiss, Danaher and Sony, his lab designed, tested and/or validated over 20 different commercial products. Examples include the FACS Aria, FACS Canto, Sony Spectral Flow Cytometer, Meta Spectral Confocal, quantum dots, and Cytobank. His academic career includes a PhD in Biophysics and an MS in Biochemistry, past joint appointments at UC Berkeley and the Lawrence Berkeley National Lab, three honorary doctorates, and authorship of over 100 peer-reviewed publications.

On the venture side, Bill has co-founded ten biotech startups and has led investment in dozens of others, usually in the seed or series A stage. Example companies include Accuri Cytometers, Zephyrus, Mission Bio, Fluent, Slingshot, CellFe, and Akadeum. Bill is a current board member for five companies, has served as Venture Partner with two Bay Area venture groups focused on early-stage investment, and is closely affiliated with four life tech incubators.

Jun Deng
Investment Partner, Joyance Partners

Jun has over a decade of experience in biomedical innovation and venture capital investment. At Joyance Partners, Jun shaped the investment strategy for health-tech and biotech areas, led the “Inception” program to bridge the relationships between academia and venture, and led more than two dozens of investments globally. So far, Jun has led or been involved in over 50 early-stage investments in the field of healthcare, medtech and biotechnologies and served two board roles. Jun is a mentor in multiple innovation ecosystems, including Singularity University and Healthtech Capital. Jun received her PhD degree in molecular physiology from UCLA.

Sami Moughrabie
Managing Partner, ATMOS Ventures

Mr. Moughrabie is the Managing Partner of ATMOS Ventures, focusing on developing Deep Technologies for large enterprise applications. Having facilitated over EUR 5 Billion in global investment transactions, Mr. Moughrabie is responsible for developing and implementing ATMOS’ short and long term global strategy by investing in the disruptive digitization of all major industry sectors.

Mr. Moughrabie is a global pioneer in the industrial applications of Artificial Intelligence and Quantum Computing, advising governments and global Fortune 500 companies on the implementation of Deep Technology solutions.

Mr. Moughrabie also serves as a Deep Technology consultant to the film industry in the US and the UK.

Previously, Mr. Moughrabie was with Bank of America’s Hedge Fund Group. He specialized in multi asset products within the Capital Markets as well as Structured Derivatives, Risk Management, and formulating strategic alliances in the alternative investments space.

Mr. Moughrabie earned his BA in Economics from the University of Chicago.

Allan W. May
Venture Partner, Medtech Convergence Fund and Founder, Life Science Angels

Allan joined the Medtech Convergence Fund as a Venture Partner in 2020. MCF is focused on the shift in therapy from intervention to prevention, invasive to non-invasive, and hospitals to the home, improving patient access while lowering the costs of managing disease. MCF is within the $3B family of funds managed by SV Health Investors.

Allan is a founder of Life Science Angels (www.lifescienceangels.org), the largest and most well-known early-stage investment group focused solely on emerging biotech, genomic, medical device, diagnostic and mobile health companies (LSA) and comprised entirely of industry veterans. LSA has invested over $75M in 70 portfolio companies and achieved 24 positive exits, and was named the Top Angel Investment Group in the United States by industry analytical source CB Insights (https://www.cbinsights.com/blog/top-angel-groups-mosaic/).

Previously, Allan was co-founder and Managing Partner of Emergent Medical Partners, a $90M venture fund, focused on medical device and diagnostics. Investments included eValve (Abbott); Nanostim (acq St Jude); CyberHeart (acq Varian); Crux (acq Volcano); StimWave and Relievant.

Allan is also Chairman of FundamentalVR, the leader in utilizing kinesthetic haptic feedback and VR to enable the commercial introduction of new medical devices and procedures, essentially replacing wet and cadaver labs.

In 2018, Allan co-founded Woodside Medical, an incubator helping commercialize U.S. medical technologies in China, with partnerships in Shanghai and Suzhou.

Allan has been founder, Chairman, CEO, or investor in over 80 medtech, biotech, and diagnostic startups. He was a co-founder and Chairman of Nanostim, developer of a Leadless Cardiac pacemaker, which was acquired by St. Jude Medical in 2013, and co-founder of Hyalex Surgical, Inc, developer of a novel artificial cartilage for total joint replacements, and is Chairman of Celero Medical, Noctrix Medical, and

Allan speaks frequently at conferences, universities, and government programs on trends and developments affecting early stage biotech and medical device investing. Allan developed medical device curriculum for Steve Blank’s inaugural groundbreaking program at University of California San Francisco to teach the Lean LaunchPad™ startup methodology in the medical device sector (LLP). He worked with Steve to bring LLP to the National Institutes of Health. LLP has also been adopted by the National Science Foundation as a core curriculum (i-Corps) for entrepreneurs. Previously, Allan served on the boards of directors of both the Kauffman Foundation’s Angel Capital Association and Angel Resource Institute, where he also served as Chairman.

Julianne Roseman
Senior Associate, Ventures, Plug and Play Tech Center

Julianne currently leads healthcare investing at Plug and Play where she focuses on digital solutions for patients, provides, and pharma. Plug and Play is a global innovation platform that includes venture capital, business development programs, and corporate innovation. In 2019, Pitchbook named Plug and Play the 2nd most active investor in the US and the 5th most active investor in healthcare services and systems. Julianne is particularly interested in preventive medicine, femtech, and digital therapeutics as well as impact investing. Her recent investments include Helium Health (healthcare software solutions for emerging markets), Rapicare (healthcare supply chain solution in Brazil), and Hyfe (AI for cough detection and analysis). Earlier in her career, Julianne worked on therapeutics investing.

David Fox
Business Angel, Corporate Development, Modality.ai
Bill Hyun, PhD
Venture Partner, Genoa Ventures
Jun Deng
Investment Partner, Joyance Partners
Sami Moughrabie
Managing Partner, ATMOS Ventures
Allan W. May
Venture Partner, Medtech Convergence Fund and Founder, Life Science Angels
Julianne Roseman
Senior Associate, Ventures, Plug and Play Tech Center
Agenda
10:00 - 10:20 am Introduction from Organisers Julia Smila, Co-Founder of Unicorn Lab
10:20 - 11:20 am Panel Discussion: "The Hottest Trends in HealthTech Investment."  See the section Speakers
11:20 - 11:30 am Introduction of Investors See the section Investors
11:30 - 12:00 pm Claridream Presentation Alex Kohen
12:00 - 12:30 pm Wellness 4 Humanity Presentation Lian Pham
12:30 - 1:00 pm VidaLuz Presentation Jessa Robuck
Startups
Claridream
Wellness 4 Humanity
VidaLuz Development
Funds
Plug and Play
Genoa Ventures
ATMOS Ventures
Medtech Convergence Fund
Life Science Angels
Joyance Partners
Testimonials
Dr. Mindy Pelz
Founder of the Reset Academy

 

I love BiohackingCongress in Silicon Valley because each speaker seems to be getting short and to the point like information-dense. Then you bring the panels up so we can interact with them. I love it. Great speakers, you brought a really good mix.I sit here knowing a lot of this information, it's like refreshing in my brain, so you guys did an incredible job!

Dasha Maximov
WhealthCo
Founder & CEO, WhealthCo

 

It was so wonderful getting to see fellow speakers and biohacking companies together again despite the challenges of 2020. I'm always looking for opportunities to learn more from and connect with specialists and this event in Menlo Park allowed me to do just that!

Kayla Osterhoff
WhealthCo
Founder & CEO, BIOCURIOUS

I'm still buzzing from the Biohacking Congress event in Menlo Park last week! The speakers were incredibly knowledgeable and provided such value in their lectures, the vendors were extremely high-quality offering biohacking goodies to take home, the attendees were just lovely, and it was so refreshing to connect in-person with my biohacking fam! I can't wait to attend the next Biohacking Congress in the Spring!

Siim Land
Founder, Body Mind Empowerment

 

The BiohackingCongress brings together groups of people who otherwise wouldn't meet and helps to overcome boundaries between health, business, and science.

Kaspars Vendelis
Co-Founder, Biohacking.lv

 

BiohackingCongress in London gathered all the European most influential biohackers, experts, and leaders in one place. To share ideas, insights, and trends. The event was valuable for its speakers’ content. But almost underappreciated is the communications and networking part in non-formal conversations during the breaks. So many valuable topics and themes were discussed before and after the official part. Two thumbs up!

Nikolina Lauc
GlycanAge
Co-Founder & CEO, GlycanAge

 

Great team with amazing energy. Really supportive, I pitched at their event, they helped prepare me with some training session and great mentors. Thank you, BiohackingCongress!

Sarah Turner
Recharge
Science Manager, Recharge

 

Thank's to Julia and the team at the BiohackingCongress for a great event. The Recharge team had a great time showing the FlexBeam, presenting on red light therapy and meeting all the top speakers and biohackers - we are looking forward to the next event - very well organized and a lot compacted into one day. Inspiring!

Vasily Nikolaev
Unicorn Lab
Fundraising Advisor

 

I know the team from Biohacking Congress for a long time; they are top-level professionals with tons of experience, connections, and lots of energy to provide superior service to their clients. They are particularly strong in helping companies in their Business Development activities in the USA and have a very strong network of investors here.

Wesley King
Coherent Capital
Biohacking Investment Banker

 

It was a pleasure being at such a well hosted and run event! I go to so many startup pitch events, and this was one of my favorites. Informative and engaging throughout, and the investors asked fantastic questions.

Pavel Stuchlik
Wellness 4 Humanity
Co-Founder, Wellness 4 Humanity. An expert in self-realization technique + application

Love these guys what they are about and changing the world for a better place!!